Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randal Baker

Surgery Grand Rapids, MI Medical Doctor

NPI 1104867480 CMS profile 231088

2060 E Paris Ave Se, Suite 100, Grand Rapids, MI 49546

Open in the dashboard

General payments

$31,885

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Randal Baker of Grand Rapids, MI is reported in the CMS Open Payments database as having received $31,885 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $879 7
2024 General $75 3
2023 General $14,908 37
2022 General $2,621 23
2021 General $3,762 8
2020 General $7,448 21
2019 General $2,191 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randal Baker
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Randal Baker were reported at $879. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Randal Baker Surgery median Middle half National median
2019 $2,191 $253 $82–$1,521 $163
2020 $7,448 $131 $40–$706 $114
2021 $3,762 $168 $50–$904 $132
2022 $2,621 $224 $76–$1,218 $149
2023 $14,908 $253 $82–$1,255 $160
2024 $75 $279 $90–$1,381 $164
2025 $879 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $16,908 33 payments
  2. W. L. Gore & Associates, Inc. $7,923 48 payments
  3. Ethicon Inc. $4,545 3 payments
  4. Baxter Healthcare $1,950 4 payments
  5. Covidien LP $229 12 payments
  6. Medtronic, Inc. $159 2 payments
  7. Boston Scientific Corporation $78 4 payments
  8. Ethicon US, LLC $34 7 payments
  9. Micro-tech Endoscopy USA, Inc. $28 1 payment
  10. Lilly USA, LLC $15 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,365 10 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,780 4 payments
  3. Education $6,000 2 payments
  4. Travel and Lodging $3,218 11 payments
  5. Food and Beverage $2,508 88 payments
  6. Gift $14 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $9,509 29 payments
  2. DA VINCI SP $7,399 4 payments
  3. GORE SEAMGUARD Bioabsorbable Staple Line Reinforce $4,871 16 payments
  4. Product in Development $2,640 3 payments
  5. PERI-STRIPS DRY $1,938 3 payments
  6. TISSEEL $1,905 2 payments
  7. FLOSEAL $1,780 1 payment
  8. GORE ENFORM Preperitoneal Biomaterial $1,144 11 payments
  9. GORE BIO-A Tissue Reinforcement $1,100 2 payments
  10. SEAMGUARD $227 13 payments
  11. Other $717 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

111

Median for General Surgery: 59

Drug cost

$5,455

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucralfate Generic 49 $3,922
Misoprostol Generic 16 $859
Omeprazole Generic 46 $674

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$30,342

Medicare's payments for the services billed

Medicare patients

42

Average age 61

Services billed

134

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 69%
Depression 62%
Diabetes 43%
Ischemic heart disease 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record